Omeprazole and Sodium Bicarbonate vs Dexlansoprazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Proton Pump Inhibitor

Omeprazole and Sodium Bicarbonate

Brand: Konvomep

First FDA approval: 2004-06-15

Proton Pump Inhibitor

Dexlansoprazole

Brand: Dexilant

First FDA approval: 2010-04-12

Lowest NADACAcquisition cost floor across all NDCs

$0.483Per unit

$4.21Per unit

Average NADACAcross all dosage forms and strengths

$4.85Up to $9.25

$5.46Up to $9.84

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

48 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$361.2MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

1.3M352K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$268Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

4Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

20Limited friction

10Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes4 manufacturers